RMTI

Company Overview — What Does ROCKWELL MEDICAL, INC. Do?

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. ROCKWELL MEDICAL, INC. (RMTI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark Strobeck and employs approximately 300 people, headquartered in WIXOM, Michigan. With a market capitalization of $37M, RMTI is one of the notable companies in the Healthcare sector.

ROCKWELL MEDICAL, INC. (RMTI) Stock Rating — Reduce (April 2026)

As of April 2026, ROCKWELL MEDICAL, INC. receives a Reduce rating with a composite score of 29.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RMTI ranks #3,416 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ROCKWELL MEDICAL, INC. ranks #525 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RMTI Stock Price and 52-Week Range

ROCKWELL MEDICAL, INC. (RMTI) currently trades at $0.91. The stock lost $0.02 (2.2%) in the most recent trading session. The 52-week high for RMTI is $2.10, which means the stock is currently trading -56.7% from its annual peak. The 52-week low is $0.78, putting the stock 16.6% above its annual trough. Recent trading volume was 157K shares, suggesting relatively thin trading activity.

Is RMTI Overvalued or Undervalued? — Valuation Analysis

ROCKWELL MEDICAL, INC. (RMTI) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.01x, versus the sector average of 2.75x. The price-to-sales ratio is 0.47x, compared to 1.66x for the average Healthcare stock.

At current multiples, ROCKWELL MEDICAL, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ROCKWELL MEDICAL, INC. Profitability — ROE, Margins, and Quality Score

ROCKWELL MEDICAL, INC. (RMTI) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -8.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -5.4% versus the sector average of -33.1%.

On a margin basis, ROCKWELL MEDICAL, INC. reports gross margins of 17.0%, compared to 71.5% for the sector. The operating margin is -4.7% (sector: -66.1%). Net profit margin stands at -5.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -38.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RMTI Debt, Balance Sheet, and Financial Health

ROCKWELL MEDICAL, INC. has a debt-to-equity ratio of 55.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.98x, indicating strong short-term liquidity. Total debt on the balance sheet is $11M. Cash and equivalents stand at $14M.

RMTI has a beta of 1.10, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ROCKWELL MEDICAL, INC. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ROCKWELL MEDICAL, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ROCKWELL MEDICAL, INC. reported revenue of $79M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-3M. Gross margin was 17.0%. Operating income came in at $-2M.

In FY 2025, ROCKWELL MEDICAL, INC. reported revenue of $69M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-5M. Gross margin was 16.9%. Revenue grew -31.8% year-over-year compared to FY 2024. Operating income came in at $-5M.

In Q3 2025, ROCKWELL MEDICAL, INC. reported revenue of $16M and earnings per share (EPS) of $-0.05. Net income for the quarter was $-2M. Gross margin was 14.3%. Revenue grew -43.8% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, ROCKWELL MEDICAL, INC. reported revenue of $16M and earnings per share (EPS) of $-0.05. Net income for the quarter was $-1M. Gross margin was 15.6%. Revenue grew -37.8% year-over-year compared to Q2 2024. Operating income came in at $-1M.

Over the past 8 quarters, ROCKWELL MEDICAL, INC. has demonstrated a growth trajectory, with revenue expanding from $26M to $79M. Investors analyzing RMTI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RMTI Dividend Yield and Income Analysis

ROCKWELL MEDICAL, INC. (RMTI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RMTI Momentum and Technical Analysis Profile

ROCKWELL MEDICAL, INC. (RMTI) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

RMTI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ROCKWELL MEDICAL, INC. (RMTI) ranks #525 out of 838 stocks based on the Blank Capital composite score. This places RMTI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RMTI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RMTI vs S&P 500 (SPY) comparison to assess how ROCKWELL MEDICAL, INC. stacks up against the broader market across all factor dimensions.

RMTI Next Earnings Date

No upcoming earnings date has been announced for ROCKWELL MEDICAL, INC. (RMTI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RMTI? — Investment Thesis Summary

The quantitative profile for ROCKWELL MEDICAL, INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 30/100) increases portfolio risk.

In summary, ROCKWELL MEDICAL, INC. (RMTI) earns a Reduce rating with a composite score of 29.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RMTI stock.

Related Resources for RMTI Investors

Explore more research and tools: RMTI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RMTI head-to-head with peers: RMTI vs AZN, RMTI vs SLGL, RMTI vs VMD.